Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

Phage-TB Mycobacteriophages to treat tuberculosis - Passed station or future promise?

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 May 2022 to 30 April 2025
Status
Running
EU funding
€239k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101063247

What the project is doing

In the project's own words, from its summary on CORDIS.

The emergence of drug-resistance to tuberculosis (TB) drugs poses an increasing challenge to TB control and new treatment options are urgently needed. Novel or repurposed antibiotics are still being introduced, but this pipeline will dry out in the near future. Bacteriophages are viruses that kill bacteria. They have been used to treat infections before the introduction of antibiotics. With the emergence of drug-resistance there is renewed interest in this ancient treatment option.

Clinical use of mycobacteriophages to treat TB and non-tuberculous mycobacterial (NTM) infections is still in its infancy. This project contributes to 3 areas in the development of clinically useful mycobacteriophage treatments for TB and NTM infections:- Phage discovery: From soil samples collected in the compounds of TB clinics and hospitals in Cape Town, South Africa, we will isolate mycobacteriophages using spot tests and plaque assays.

DNA of newly discovered mycobacteriophages will be sequenced and during the return phase of this project I will select promising mycobacteriophages with lytic effect against TB or NTM infections, that can be used for development of phage cocktails for clinical use. - Phage inhalation method: the efficiency of phage treatment is dependent upon the phage concentration reached at the site of disease. Phages that can attack M tuberculosis have long tails which might be vulnerable to manipulation.

We will optimize an inhalation method leaving the phages intact and functional.- Preparation for a clinical trial: an existing mycobacteriophage cocktail active against TB will be used for a first clinical study in humans to assess dosing, safety and efficiency. If our mycobacteriophage hunt is successful, and the translation can be made into purified and adequately dosed administration of mycobacteriophages, a virtually inexhaustible addition will be made to the therapeutic armamentarium for drug-resistant as well as drug-sensitive TB and NTM infections.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator
Stellenbosch UniversityStellenboschSouth AfricaAssociatedpartner
Task Foundation NpcCape TownSouth AfricaAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI